2018
DOI: 10.1007/978-3-319-95046-4_26
|View full text |Cite
|
Sign up to set email alerts
|

Leber Congenital Amaurosis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
45
0
4

Year Published

2019
2019
2024
2024

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 59 publications
(51 citation statements)
references
References 3 publications
2
45
0
4
Order By: Relevance
“…Disease onset can be from early childhood, however, some patients do not exhibit symptoms until after the first decade of life [290][291][292]. Additional CRB1 clinically relevant features include macular atrophy, keratoconus, Coats-like exudative vasculopathy, RP without PPRPE, pigmented paravenous chorioretinal atrophy, and nanophthalmos [288,[293][294][295][296][297].…”
Section: Crb1 and Leber Congenital Amaurosismentioning
confidence: 99%
“…Disease onset can be from early childhood, however, some patients do not exhibit symptoms until after the first decade of life [290][291][292]. Additional CRB1 clinically relevant features include macular atrophy, keratoconus, Coats-like exudative vasculopathy, RP without PPRPE, pigmented paravenous chorioretinal atrophy, and nanophthalmos [288,[293][294][295][296][297].…”
Section: Crb1 and Leber Congenital Amaurosismentioning
confidence: 99%
“…Down syndrome increases the risk of keratoconus progression, thereby increasing the risk of acute hydrops [20]. Retinitis pigmentosa, Leber Congenital Amaurosis (LCA), floppy eye lid syndrome, and Ehler-Danlos syndrome are other risk factors for progressive keratoconus, which are followed by the incident of hydrops [21,22,23,24]. Pregnancy and lactation are also the critical but temporary risk factors [25].…”
Section: Predisposing Factorsmentioning
confidence: 99%
“…One example is Leber congenital amaurosis (LCA) which is one of the major causes of blindness among children. Mutations in the CEP290, CRB1, GUCY2D or RPE65 are the most common causes of this disorder (Tsang and Sharma 2018). In 2017, U.S. Food and Drug Administration (FDA) approved Luxturna (Spark Therapeutics) a gene transfer therapy where a healthy copy of RPE65 is delivered to the diseased retina using an Adeno-Associated Viral vector (Smalley 2017).…”
Section: Repairing Faulty Genomesmentioning
confidence: 99%